BRD2 and ovarian dysfunction: A trial by Allegra et al. reported an incidence of ovarian failure (defined as amenorrhea for ≥3 months with blood FSH levels ≥30 mIU/mL) of 34% when bevacizumab was administered and an incidence of 2% in the control group.